Shares of Hospira (HSP) tumbled 2.81% to close the trading session on Aug 19 at $53.92 per share, following the company’s decision to file a lawsuit against the FDA over approvals granted to generic ...
In the Precedex matter, Hospira reacted with lightning speed. The day after FDA’s determination the company was in court, and late that night, FDA was stopped, at least for 14 days (until September 2) ...
Hospira's reprieve from generic Precedex competition was short-lived. The U.S. district court that temporarily stopped Precedex generics has now decided to let the copycats roll. And that could mean ...
Dexmedetomidine HCl in 0.9% NaCl; 4mcg/mL; soln for IV infusion. Precedex (dexmedetomidine hydrochloride) injection 200 mcg/2 mL (100 mcg/mL) is clear and colorless. The strength is based on the ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Hospira Inc. is suing fellow pharma manufacturer Akorn Inc ...
Hospira has been in the news regarding Precedex for quite a while now. Last month, the FDA granted approval to companies like Mylan to launch their generic versions of the product. However, Hospira ...
To earn CME related to this news article, click here. January 2, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions for clofarabine injection, dexmedetomidine HCl ...
After a bench trial, the US District Court for the District of Delaware found several Hospira patents covering a diluted, “ready-to-use” composition of dexmedetomidine obvious in view of the ...
LAKE FOREST, Ill., Oct. 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE:HSP), a global specialty pharmaceutical and medication delivery company, announced today that ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. (AP) — Drug and medical device maker Hospira Inc. said ...
The FDA has approved Precedex (dexmedetomidine HCl, from Hospira) injection for the sedation of non-intubated patients prior to and/or during surgical and other procedures. This approval is based on ...
Shares of Hospira ( HSP) tumbled 2.81% to close the trading session on Aug 19 at $53.92 per share, following the company's decision to file a lawsuit against the FDA over approvals granted to generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback